Practical considerations and guidelines for the management of community-acquired pneumonia

被引:42
作者
Finch, RG [1 ]
Woodhead, MA
机构
[1] City Hosp, Dept Microbiol & Infect Dis, Nottingham NG5 1PB, England
[2] Univ Nottingham, Nottingham NG5 1PB, England
[3] Manchester Royal Infirm, Dept Gen & Resp Med, Manchester M13 9WL, Lancs, England
关键词
D O I
10.2165/00003495-199855010-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Community-acquired pneumonia (CAP) is a common condition which has a significant mortality. The management of a patient with CAP is centred around assessment and correction of gas exchange and fluid balance together with administration of appropriate antibiotics. Up to 10 different pathogens regularly cause CAP, of which Streptococcus pneumoniae is the most important. These different pathogens cannot be distinguished by clinical features or simple laboratory tests. Microbiological tests are slow and insensitive, so empirical therapy is necessary, at least initially. Accurate assessment of illness severity is the most important factor determining initial management, since this assists the decision of whether to admit the patient to hospital in addition to guiding antibiotic choice and route of administration. Two different approaches to severity assessment are outlined. Our antibiotic recommendation for empirical therapy for the patient managed at home and the previously fit patient admitted to hospital is amoxicillin. Amoxicillin/clavulanate plus a macrolide is our choice for the severely ill previously fit patient and a third-generation cephalosporin plus a macrolide is recommended for the severely ill patient with comorbidity. Alternative pathogens and specific treatment regimens are also described. There may be several causes of treatment failure, and in patients who fail to respond to therapy, it is essential to review all the initial clinical and laboratory information, which if necessary must be repeated.
引用
收藏
页码:31 / 45
页数:15
相关论文
共 62 条
  • [1] THE OUTCOME OF COMMUNITY ACQUIRED PNEUMONIA TREATED ON THE INTENSIVE-CARE UNIT
    ALKHAYER, M
    JENKINS, PF
    HARRISON, BDW
    [J]. RESPIRATORY MEDICINE, 1990, 84 (01) : 13 - 16
  • [2] ALMIRALL J, 1993, EUR RESPIR J, V6, P14
  • [3] ANDREWS BE, 1987, Q J MED, V62, P195
  • [4] PROSPECTIVE-STUDY ON THE ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN AND ADULTS IN SPAIN
    AUSINA, V
    COLL, P
    SAMBEAT, M
    PUIG, I
    CONDOM, MJ
    LUQUIN, M
    BALLESTER, F
    PRATS, G
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (03) : 343 - 347
  • [5] BARTLETT CLR, 1992, RESP MED, V86, P7
  • [6] COMMUNITY-ACQUIRED PNEUMONIA
    BARTLETT, JG
    MUNDY, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) : 1618 - 1624
  • [7] ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA IN PATIENTS REQUIRING HOSPITALIZATION
    BERNTSSON, E
    BLOMBERG, J
    LAGERGARD, T
    TROLLFORS, B
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1985, 4 (03) : 268 - 272
  • [8] ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA IN OUT-PATIENTS
    BERNTSSON, E
    LAGERGARD, T
    STRANNEGARD, O
    TROLLFORS, B
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (04) : 446 - 447
  • [9] ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA - A PROSPECTIVE-STUDY AMONG ADULTS REQUIRING ADMISSION TO HOSPITAL
    BOHTE, R
    VANFURTH, R
    VANDENBROEK, PJ
    [J]. THORAX, 1995, 50 (05) : 543 - 547
  • [10] CHLAMYDIA-PNEUMONIAE - DEFINING THE CLINICAL SPECTRUM OF INFECTION REQUIRES PRECISE LABORATORY DIAGNOSIS
    BOURKE, SJ
    LIGHTFOOT, NF
    [J]. THORAX, 1995, 50 : S43 - S48